Skip to main content
. 2020 Mar 18;146(6):1559–1566. doi: 10.1007/s00432-020-03184-z

Table 2.

Unadjusted outcome and risk factors

Group of patients N OS, median [months] 4YS [%] 5YS [%] Logrank
p-value
Total 1033 30.3 30.4 22
 1990–1994 279 24.2 22.6 14  < 0.0001
 1995–1999 408 29.6 29.7 23
 2000–2004 143 36.5 36.4 30.8
 2005–2009 203 37.8 37.4 24.6
 Bone only 215 44.8 48.8 36.7  < 0.0001
 Liver and/or lung 608 24.7 23.5 16.5
 Other 210 31.8 29.1 21
 HR +  613 37.3 36.4 25.9  < 0.0001
 HR − 307 19.7 14.3 10.1
 HR unknown 113 31.1 37.2 29.2
 Initial metastasis 126 38.6 38.1 29.4  < 0.0001
 DFI < 18 month 210 18.4 17.1 11.4
 DFI 18–35 month 226 25.4 21.7 15
 DFI > 35 month 471 37.5 37.4 27.2
 Age < 50 years 421 29.6 28.7 20.9 0.6087
 Age ≥ 50 years 612 31.6 30.7 22.1

Median overall survival, probability of 4-year and 5-year overall survival of patients with metastatic breast cancer, according to time period of diagnosis of metastatic disease and according to prognostic factors

OS overall survival. 4YS, 4-year overall survival. 5YS 5-year overall survival